Evidence map›Paper›PMID 42386932›Full record

ArticleNature genetics2026

U2AF1 mutations rescue deleterious exon skipping induced by KRAS mutations.

David M Walter, Katherine Cho, Smruthy Sivakumar, Daniel Denney, Iris T Lee, Anders B Dohlman, Jakob M Heinz, Ethan Shurberg, Kevin X Jiang, Akansha A Gupta and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

David M WalterDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Katherine ChoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Smruthy SivakumarFoundation Medicine Inc., Boston, MA, USA.
Daniel DenneyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Iris T LeeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-1549-706X
Anders B DohlmanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-3473-2878
Jakob M HeinzDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Ethan ShurbergDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Kevin X JiangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Akansha A GuptaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Garrett M FramptonFoundation Medicine Inc., Boston, MA, USA.ORCID http://orcid.org/0000-0002-2361-2750
Matthew MeyersonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Matthew_Meyerson@dfci.harvard.edu.ORCID http://orcid.org/0000-0002-9133-8108

Funding

NKX2-1 Enhancer Amplification and Lineage Addiction in Lung AdenocarcinomaR35CA197568 · NCI · DANA-FARBER CANCER INST · PI Matthew L. Meyerson · 2015 to 2026
$12.4M
American Cancer Society (American Cancer Society, Inc.) Research ProfessorshipDamon Runyon Cancer Research Foundation (Cancer Research Fund of the Damon Runyon-Walter Winchell Foundation) DRG-2449-21Damon Runyon Cancer Research Foundation (Cancer Research Fund of the Damon Runyon-Walter Winchell Foundation) DRG-2504-23NCI NIH HHS R35 CA197568
6 · The paper itself

Abstract

The mechanisms by which mutations of splicing factor gene U2AF1 contribute to lung adenocarcinoma pathogenesis are not well understood. Here we used prime editing to modify the endogenous U2AF1 gene in lung adenocarcinoma cells and assessed the impact on alternative splicing. One specific KRAS mutation, G12S, led to skipping of KRAS exon 2 and generation of a nonfunctional KRAS transcript. However, expression of the U2AF1

Indexed as

AdenocarcinomaExonsLung NeoplasmsMutationProto-Oncogene Proteins p21(ras)RibonucleoproteinsSplicing Factor U2AFAdenocarcinoma of LungAlternative SplicingCell Line, TumorHumansKRAS protein, humanProto-Oncogene Proteins p21(ras)RibonucleoproteinsSplicing Factor U2AFU2AF1 protein, human

Identifiers

PMID42386932

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.